STOCK TITAN

Yulong Eco-Matls Stock Price, News & Analysis

YECO OTC

Company Description

YULONG ECO MATERIALS LTD, now known as EV Biologics Corp, is a biotechnology company based in Wyoming, USA. Their focus lies in developing stem cell-derived exosome-based therapeutic products and biocompatible formulations to enhance bioactivity and potency. Through advanced biomanufacturing, bioengineering, and bioinformatics, they aim to optimize nanoparticle-based biologics for various clinical applications, including regenerative medicine and longevity.

EV Biologics also owns Excyte, a subsidiary focused on developing biotherapeutics from living cells. Their innovative approach utilizes nanotherapeutic platforms to deliver bioactive molecules to target cells, combat aging, and promote longevity. With a strong emphasis on research and development, as well as collaboration with commercial partners, EV Biologics is poised to revolutionize modern medicine with their groundbreaking therapeutic solutions.

Stock Performance

$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$880.4K
Market Cap
10.2M
Shares outstanding

SEC Filings

No SEC filings available for Yulong Eco-Matls.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Diluted EPS (TTM)
Operating Cash Flow
Net Profit Margin
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Yulong Eco-Matls (YECO)?

The current stock price of Yulong Eco-Matls (YECO) is $0.0861 as of April 24, 2025.

What is the market cap of Yulong Eco-Matls (YECO)?

The market cap of Yulong Eco-Matls (YECO) is approximately 880.4K.

What is YULONG ECO MATERIALS LTD known for?

YULONG ECO MATERIALS LTD, now EV Biologics Corp, is renowned for developing stem cell-derived exosome-based therapeutic products and biocompatible formulations to enhance bioactivity and potency.

What is EV Biologics Corp's focus areas?

EV Biologics Corp primarily focuses on biomanufacturing, bioengineering, and bioinformatics to optimize nanoparticle-based biologics for diverse clinical applications, including regenerative medicine and longevity.

What subsidiary does EV Biologics Corp own?

EV Biologics Corp owns Excyte, a subsidiary dedicated to developing biotherapeutics from living cells. Excyte uses nanotherapeutic platforms to deliver bioactive molecules, combat aging, and promote longevity.

How does EV Biologics Corp plan to revolutionize modern medicine?

EV Biologics Corp aims to revolutionize modern medicine by utilizing nanotherapeutic platforms, collaborative research and development, and innovative bioengineering to create groundbreaking therapeutic solutions.

What sets EV Biologics Corp apart in the biotechnology industry?

EV Biologics Corp stands out in the biotechnology industry due to its focus on stem cell-derived exosome-based therapeutics, biocompatible formulations, and cutting-edge bioengineering innovations.

What clinical applications does EV Biologics Corp target?

EV Biologics Corp targets a wide range of clinical applications, including regenerative medicine and longevity, through the development of nanoparticle-based biologics with enhanced bioactivity and potency.

Where is EV Biologics Corp based?

EV Biologics Corp is based in Wyoming, USA, and operates under the former name YULONG ECO MATERIALS LTD.

What recent achievements has EV Biologics Corp celebrated?

EV Biologics Corp has recently closed a significant interest-free loan, launched regenerative products in Asia, started audits for name/symbol changes, and filed for a trademark under the product name: EcoCura.

What future goals does EV Biologics Corp aim to achieve?

EV Biologics Corp has ambitious goals of developing versatile therapeutics, enabling safe and effective treatments for various clinical conditions, and promoting better health and longevity through their innovative therapeutic solutions.

How does EV Biologics Corp approach research and development?

EV Biologics Corp focuses on extensive research and development, collaborating with commercial partners, and innovating in biomanufacturing, bioengineering, and bioinformatics to create precision nanotherapeutics for diverse clinical indications.